Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity.

Tsaktanis T, Ammon L, Lößlein L, Peter A, Vandrey O, Naumann UJ, Behne M, Cook LJ, Levy M, Yeaman MR, Bennett JL, Rothhammer V; Guthy-Jackson Charitable Foundation CIRCLES Study Group.